Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: Case reports and review of the literature

Breast Cancer Research and Treatment

Volumn 106, Issue 3, 2007, Pages 315-318

  Jhaveri, Komal ^a   Halperin, Peter ^a   Shin, Sandra J ^a   Vahdat, Linda ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aromatase inhibitors; Breast Cancer; Dermatologic; Erythema Nodosum; Skin

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; LETROZOLE; PACLITAXEL; TAMOXIFEN; THIOTEPA;

ADJUVANT THERAPY; ADULT; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL TRIAL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; TREATMENT PLANNING; TREATMENT RESPONSE;

AROMATASE INHIBITORS; BREAST NEOPLASMS; ERYTHEMA NODOSUM; FEMALE; HUMANS; MIDDLE AGED;

EID: 35648963609     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9518-7     Document Type: Review

References (25)

1. Ian E, Smith MD, Mitch Dowsett (2003) Aromatase inhibitors in breast cancer. NEJM 348(24):2431-2442
2. Diana E, Lake MD, Clifford Hudis MD (2002) Aromatse inhibitors in breast cancer: an update. Cancer Control 9(6):490-498
3. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606 [Erratum, J Clin Oncol 2001; 19:3302.][Abstract/Full Text]
4. Bonneterre J, Thurlimann B, Robertson JFR et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757 [Abstract/Full Text]
5. ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131-2139 [Erratum, Lancet 2002; 360:1520.][CrossRef][ISI][Medline]
6. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A (2005) Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2807-2809
7. Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810
8. Richard Eastell, Rosemary Hannon (2005) Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 95(1-5):151-154
9. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
10. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of Exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
11. http://www.cancercare.on.ca/pdfmedicationinfo/Letrozole.pdf, http://www.cancercare.onca/pdfmedicationinfo/Anastrozole.pdf, http://www.cancercare.onca/pdfmedicationinfo/Exesmestane.pdf.
12. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816
13. Ellis MJ, Coop A, Singh B et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531
14. th annual San Antonio breast cancer symposium December 2003
15. Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K (2005) Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. Ann Rheum Diseases 64:651-652
16. Drago F, Arditi M, Rebora A (1990) Tamoxifen and purpuric vasculitis. Ann Int Med 112:965-966
17. Sereda D, Werth VP (2006) Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 142(1):70-72
18. Reed MJ, Purohit A (2001) Review: aromatase regulation and breast cancer. Clinical Endocrinol 54:563-571
19. 4, Shin-ichi Hayashi (2005) Tumor-Stromal interaction through the estrogen-signaling pathway in human breast cancer: cell and tumor biology. Cancer Res 65:4653-4662
20. Svenja Labunski, Guido Posern, Stephan Ludwig, Kundt G, Bröcker Eva-B, Manfred Kunz (2001) Tumour necrosis factor-a promoter polymorphism in erythema nodosum. Acta Dermato-Venereologica 81(1):18-21
21. Sampio EP, Moraes MO, Nery JAC, Moraes, Santos AR, Matos HC, Sarno EN (1998) Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol 111(2):300-308 (9)
22. Psychos DN, Voulgari PV, Skopouli FN, Drosos AA, Moutsopoulos HM (2000) Erythema nodosum: the underlying conditions. Clin Rheumatol 19(3):212-216
23. Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R (2004) Erythema nodosum: an experience of 10 years. Scand J Infect Dis 36(6-7):424-427
24. Robert Sullivan, Holly Clowers-Webb, Mark DP, Davis (2005) Erythema Nodosum: a presenting sign of Acute Myelogenous Leukemia. Cutis 76(2):114-116
25. 2 (-) 1. Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain; and 2. Department of Dermatology, Hospital General Universitario, Universidad de Valencia, Valencia, SpainErythema Nodosum. Dermatol Online J 8(1):4